Gene ther­a­py up­start re­cruits more ex-AveX­is tal­ent; I-Mab re­veals first-half re­sults

It hasn’t been hard to see where Sean Nolan went look­ing for the tal­ent need­ed to make Taysha in­to a lead­ing play­er in the bustling gene ther­a­py field.

Mon­day morn­ing the com­pa­ny, where Nolan holds the chair­man’s post, put out word that Taysha re­cruit­ed the ex-CMO and ex-CFO at AveX­is to come on­to the board in the wake of a $94 mil­lion crossover raise.

In this en­vi­ron­ment, it’s yet an­oth­er sign that Nolan and the top crew could have their sights set on an IPO as the biotech up­start com­pletes the full team.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN